ATE150316T1 - Verwendung von menschlichem igf-i - Google Patents
Verwendung von menschlichem igf-iInfo
- Publication number
- ATE150316T1 ATE150316T1 AT92903240T AT92903240T ATE150316T1 AT E150316 T1 ATE150316 T1 AT E150316T1 AT 92903240 T AT92903240 T AT 92903240T AT 92903240 T AT92903240 T AT 92903240T AT E150316 T1 ATE150316 T1 AT E150316T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- prevention
- human igf
- cardiac
- medicament
- Prior art date
Links
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 title abstract 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 abstract 3
- 208000020446 Cardiac disease Diseases 0.000 abstract 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 208000019622 heart disease Diseases 0.000 abstract 2
- 102000044162 human IGF1 Human genes 0.000 abstract 2
- 208000010125 myocardial infarction Diseases 0.000 abstract 2
- 206010007556 Cardiac failure acute Diseases 0.000 abstract 1
- 208000031229 Cardiomyopathies Diseases 0.000 abstract 1
- 102000008934 Muscle Proteins Human genes 0.000 abstract 1
- 108010074084 Muscle Proteins Proteins 0.000 abstract 1
- 208000009525 Myocarditis Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 102000023732 binding proteins Human genes 0.000 abstract 1
- 108091008324 binding proteins Proteins 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 210000004165 myocardium Anatomy 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000001243 protein synthesis Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000014616 translation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9100099A SE9100099D0 (sv) | 1991-01-11 | 1991-01-11 | Use of growth factor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE150316T1 true ATE150316T1 (de) | 1997-04-15 |
Family
ID=20381598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT92903240T ATE150316T1 (de) | 1991-01-11 | 1992-01-10 | Verwendung von menschlichem igf-i |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5434134A (de) |
| EP (2) | EP0566641B1 (de) |
| JP (1) | JP3566283B2 (de) |
| AT (1) | ATE150316T1 (de) |
| AU (1) | AU657729B2 (de) |
| CA (1) | CA2099257A1 (de) |
| DE (1) | DE69218406T2 (de) |
| DK (1) | DK0566641T3 (de) |
| ES (1) | ES2101833T3 (de) |
| GR (1) | GR3023614T3 (de) |
| IE (1) | IE914392A1 (de) |
| IL (1) | IL100585A (de) |
| NZ (1) | NZ241108A (de) |
| SE (1) | SE9100099D0 (de) |
| WO (1) | WO1992011865A1 (de) |
| ZA (1) | ZA919977B (de) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5273961A (en) * | 1992-09-22 | 1993-12-28 | Genentech, Inc. | Method of prophylaxis of acute renal failure |
| US5610134A (en) * | 1994-04-15 | 1997-03-11 | Genentech, Inc. | Treatment of congestive heart failure |
| US5661122A (en) * | 1994-04-15 | 1997-08-26 | Genentech, Inc. | Treatment of congestive heart failure |
| US5935924A (en) * | 1994-04-15 | 1999-08-10 | Genentech, Inc. | Treatment of congestive heart failure |
| SE9402331D0 (sv) * | 1994-07-01 | 1994-07-01 | Pharmacia Ab | New use |
| US5712249A (en) * | 1994-09-08 | 1998-01-27 | Ciba-Geigy Corporation | Use of insulin-like growth factors I and II for inhibition of inflammatory response |
| WO1996010401A1 (en) * | 1994-10-04 | 1996-04-11 | Emory University | Methods for regulation of insulin-like growth factor i receptor |
| US5741776A (en) * | 1995-05-22 | 1998-04-21 | Genentech, Inc. | Method of administration of IGF-I |
| US5565428A (en) * | 1995-05-22 | 1996-10-15 | Genentech, Inc. | Method of administration of IGF-I |
| GB9605124D0 (en) | 1996-03-11 | 1996-05-08 | Royal Free Hosp School Med | Method of treating muscular disorders |
| EP1566180A3 (de) * | 1996-08-30 | 2007-08-08 | Eli Lilly & Company | Verwendung von GLP-1 oder Analogen zur Behandlung von Myokardinfarkt |
| US6277819B1 (en) * | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
| US6025368A (en) * | 1997-02-25 | 2000-02-15 | Celtrix Pharmaceuticals, Inc. | Method for treating the symptoms of chronic stress-related disorders using IGF |
| US6514937B1 (en) | 1997-02-25 | 2003-02-04 | Celtrix Pharmaceuticals, Inc. | Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3 |
| US6015786A (en) * | 1997-02-25 | 2000-01-18 | Celtrix Pharmaceuticals, Inc. | Method for increasing sex steroid levels using IGF or IGF/IGFBP-3 |
| US6420518B1 (en) | 1997-04-04 | 2002-07-16 | Genetech, Inc. | Insulin-like growth factor agonist molecules |
| US6121416A (en) | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
| US6335317B1 (en) | 1998-04-10 | 2002-01-01 | Emory University | Use of gut-trophic growth factors to improve oxidative status |
| US6300271B1 (en) * | 1998-05-18 | 2001-10-09 | Phillips Petroleum Company | Compositions that can produce polymers |
| JP2002528390A (ja) * | 1998-10-02 | 2002-09-03 | セント エリザベス メディカル センター， インコーポレイテッド | 細胞の生存を増強するためのａｋｔ組成物 |
| US7368420B1 (en) | 1998-10-02 | 2008-05-06 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Akt compositions for enhancing survival of cells |
| ES2234560T3 (es) | 1999-01-06 | 2005-07-01 | Genentech, Inc. | Variante mutante del factor de crecimiento de tipo insulina (igf-i). |
| SE9901634D0 (sv) * | 1999-05-05 | 1999-05-05 | Sahltech Ab | Treatment of myocardial infarction with a substance related to the growth hormone axis |
| GB0011278D0 (en) | 2000-05-10 | 2000-06-28 | Univ London | Repair of nerve damage |
| ATE389416T1 (de) | 2000-05-16 | 2008-04-15 | Genentech Inc | Behandlung von knorpelerkrankungen |
| US7862810B2 (en) | 2000-07-31 | 2011-01-04 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
| US20110091428A1 (en) * | 2000-07-31 | 2011-04-21 | New York Medical College | Compositions of adult organ stem cells and uses thereof |
| US7547674B2 (en) | 2001-06-06 | 2009-06-16 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
| US20020098167A1 (en) * | 2000-07-31 | 2002-07-25 | Piero Anversa | Methods and compositions for the repair and/or regeneration of damaged myocardium |
| AU2002211688A1 (en) * | 2000-10-13 | 2002-04-29 | Chiron Corporation | Method for treating ischemic events affecting the central nervous system |
| DK1772464T3 (da) | 2001-02-09 | 2009-12-14 | Genentech Inc | Fremgangsmåder til identificering af indirekte agonister af IGF-1 |
| GB0202906D0 (en) | 2002-02-07 | 2002-03-27 | Univ London | Prevention of myocardial damage |
| GB0426154D0 (en) * | 2004-11-29 | 2004-12-29 | European Molecular Biology Lab Embl | IGF-1 novel peptides |
| US20080103457A1 (en) * | 2005-01-11 | 2008-05-01 | Heart Failure Technologies, Inc. University Enterprise Laboratories (Uel) | Method and System for Treating Heart Failure |
| US20090012499A1 (en) * | 2005-02-08 | 2009-01-08 | Japan As Rep. By Pres. Of Nat. Cardiovascular Ctr. | Novel method for treating chronic severe heart failure by using insulin-like growth factor-1 (igf-1) |
| AU2008323719B2 (en) | 2007-11-09 | 2013-04-04 | New York Medical College | Methods for the repair and/or regeneration of damaged myocardium using variants of hepatocyte growth factor |
| EP2229177A1 (de) * | 2007-11-30 | 2010-09-22 | New York Medical College | Verfahren zur isolierung von nicht-alternden kardialen stammzellen und ihre verwendungen |
| EP2245140A2 (de) * | 2007-11-30 | 2010-11-03 | New York Medical College | Zusammensetzungen mit hdac-inhibitoren und verfahren zu deren verwendung bei der wiederherstellung der stammzellenfunktion und vorbeugung von herzversagen |
| AU2008334036B2 (en) | 2007-11-30 | 2014-05-29 | New York Medical College | Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells |
| CA2743698A1 (en) | 2007-11-30 | 2009-06-11 | New York Medical College | Compositions comprising vascular and myocyte progenitor cells and methods of their use |
| US8512696B2 (en) | 2007-11-30 | 2013-08-20 | Autologous, Llc | Methods of isolating non-senescent cardiac stem cells and uses thereof |
| CN110812369A (zh) * | 2018-08-10 | 2020-02-21 | 浙江楚沅生物科技有限公司 | 用于治疗组织坏死或改善心脏功能的药物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4272649A (en) * | 1979-04-09 | 1981-06-09 | Williams Electronics, Inc. | Processor controlled sound synthesizer |
| US4738921A (en) * | 1984-09-27 | 1988-04-19 | Eli Lilly And Company | Derivative of the tryptophan operon for expression of fused gene products |
| SE8703625D0 (sv) * | 1987-09-18 | 1987-09-18 | Kabivitrum Ab | New medical use |
| US4988675A (en) * | 1988-02-05 | 1991-01-29 | Ciba-Geigy Corporation | Method for preventing secondary effects |
-
1991
- 1991-01-11 SE SE9100099A patent/SE9100099D0/xx unknown
- 1991-12-17 IE IE439291A patent/IE914392A1/en not_active IP Right Cessation
- 1991-12-19 ZA ZA919977A patent/ZA919977B/xx unknown
- 1991-12-20 NZ NZ241108A patent/NZ241108A/en not_active IP Right Cessation
-
1992
- 1992-01-05 IL IL100585A patent/IL100585A/xx not_active IP Right Cessation
- 1992-01-10 WO PCT/SE1992/000009 patent/WO1992011865A1/en active IP Right Grant
- 1992-01-10 JP JP50361192A patent/JP3566283B2/ja not_active Expired - Fee Related
- 1992-01-10 AU AU11669/92A patent/AU657729B2/en not_active Ceased
- 1992-01-10 AT AT92903240T patent/ATE150316T1/de not_active IP Right Cessation
- 1992-01-10 US US08/084,232 patent/US5434134A/en not_active Expired - Fee Related
- 1992-01-10 EP EP92903240A patent/EP0566641B1/de not_active Expired - Lifetime
- 1992-01-10 DK DK92903240.7T patent/DK0566641T3/da active
- 1992-01-10 ES ES92903240T patent/ES2101833T3/es not_active Expired - Lifetime
- 1992-01-10 CA CA002099257A patent/CA2099257A1/en not_active Abandoned
- 1992-01-10 DE DE69218406T patent/DE69218406T2/de not_active Expired - Fee Related
- 1992-01-10 EP EP92850004A patent/EP0501937B1/de not_active Expired - Lifetime
-
1997
- 1997-05-30 GR GR970401258T patent/GR3023614T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU657729B2 (en) | 1995-03-23 |
| ZA919977B (en) | 1992-09-30 |
| JP3566283B2 (ja) | 2004-09-15 |
| EP0566641A1 (de) | 1993-10-27 |
| IL100585A0 (en) | 1992-09-06 |
| ES2101833T3 (es) | 1997-07-16 |
| NZ241108A (en) | 1997-06-24 |
| EP0501937B1 (de) | 1997-03-19 |
| SE9100099D0 (sv) | 1991-01-11 |
| WO1992011865A1 (en) | 1992-07-23 |
| US5434134A (en) | 1995-07-18 |
| CA2099257A1 (en) | 1992-07-12 |
| DE69218406D1 (de) | 1997-04-24 |
| EP0501937A1 (de) | 1992-09-02 |
| DE69218406T2 (de) | 1997-07-10 |
| GR3023614T3 (en) | 1997-08-29 |
| DK0566641T3 (da) | 1997-10-06 |
| AU1166992A (en) | 1992-08-17 |
| JPH06504286A (ja) | 1994-05-19 |
| EP0566641B1 (de) | 1997-03-19 |
| IE914392A1 (en) | 1992-07-15 |
| IL100585A (en) | 1997-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE150316T1 (de) | Verwendung von menschlichem igf-i | |
| DK0754048T3 (da) | Behandling af partielt væksthormon-insentivitetssyndrom | |
| DE69535491D1 (de) | Niedermolekulare Peptide zur Stimulation der Sekretion von Wachstumshormonen | |
| UA42747C2 (uk) | Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту | |
| FI932385A0 (fi) | Behandling av osteoporos genom anvaendning av somatoliberin (GRF) i en kombination med paratyreoideahormon (PTH) | |
| ATE193541T1 (de) | Insulinotropes hormon | |
| DE69631544D1 (de) | Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse | |
| DE3851776D1 (de) | Verwendung von IGF-II zur Behandlung von Knochenkrankheiten. | |
| DE69841279D1 (de) | Verwendung von humanem Parathyroid-hormon | |
| ATE273997T1 (de) | Zyklische hexapeptid somatostatin analoga | |
| IL145310A0 (en) | Vascular adhesion molecules and modulation of their function | |
| CA2334941A1 (en) | Tnf-derived peptides for use in treating oedema | |
| ATE118815T1 (de) | Gewebs-plasminogen-aktivator-analoge mit modifizierten wachstumsfaktordomänen. | |
| ES2087337T3 (es) | Composiciones de implantes que contienen una proteina, peptido o polipeptido biologicamente activos. | |
| ATE59781T1 (de) | Potenzierung von prazosin. | |
| AR036591A1 (es) | Uso de la hl en hiperestimulacion ovarica controlada | |
| IT214492Z2 (it) | Scarpa con suola zavorrabile per uso sportivo o terapeutico. | |
| DK0555785T3 (da) | Glat-muskel-mitogent stof og DNA, der koder herfor | |
| NO921595D0 (no) | Superaktive grf analoger | |
| DE69113773D1 (de) | Verwendung von 3-aryl-5-alkylthio-4H-1,2,4-triazolen zur Behandlung von Überreflexen infolge von Rückenmarkstrauma. | |
| KÜSSWETTER et al. | Healing of reconstructed ligament insertion | |
| TH45445A (th) | การใช้สารคล้ายๆกับ glp-1 และอนุพันธ์ต่างๆ ของ glp-1 ทางกระแสโลหิตในการปรับควบคุมดูแลความอ้วนมากเกินไป | |
| ITAP930004U1 (it) | Sistema di correzione del procurvato e del recurvato per allungatori di arti | |
| RU93058426A (ru) | Антогонист галанина, способ его получения, пептид, фармацевтический состав и способ лечения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |